Latest news with #BioMark
Globe and Mail
12-05-2025
- Business
- Globe and Mail
Thinly Traded, Big Potential: This Biotech's Blood Test Proves Its Precision
An under-the-radar biotech caught our attention today. While the company's news provides meaningful validation for its blood-based test, the stock trades thinly, limiting any immediate market reaction to key developments. Still, the story was too compelling for us to ignore. BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) announced this morning the publication of a landmark study in the International Journal of Molecular Sciences, validating the high specificity and accuracy of its blood-based test for early-stage non-small cell lung cancer (NSCLC). The research, titled 'Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection,' demonstrated the effectiveness of BioMark's metabolomics and machine learning technology in distinguishing lung cancer from a range of non-cancerous lung diseases, a critical challenge in early diagnosis. The study analyzed 680 archived plasma samples in the discovery phase and validated findings with an independent set of 216 samples. A standout feature was the inclusion of a clinically complex control group comprising not just healthy individuals but also patients with various non-malignant lung conditions. This rigorous design ensured the test was assessed under real-world conditions. The models achieved over 93% AUROC for stage I–II NSCLC, underlining the strength and reliability of BioMark's diagnostic approach, especially for early detection. Company executives hailed the study as a major milestone toward clinical adoption. Dr. Jean-François Haince emphasized the importance of testing against complex cases to prove specificity, while CEO Rashid Ahmed Bux highlighted the publication as external validation of years of work. With current screening methods like low-dose CT scans often leading to false positives, BioMark's minimally invasive blood test could offer a more accurate, patient-friendly alternative for early lung cancer detection and intervention. As noted earlier, shares of BUX and its U.S. counterpart did not trade on the news—an unfortunate outcome considering the significance of the announcement. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc. Phone: (800) 558-4560 Ext: 101
Yahoo
08-05-2025
- Business
- Yahoo
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market under the symbol "BMKDF" on May 8th, 2025. Additionally, the Company's common shares will maintain its eligibility for settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp., which facilitates the electronic clearing and settlement of publicly traded companies in the United States. Trading on the OTCQB is expected to complement the Company's existing listing on the Canadian Securities Exchange (CSE) under its existing symbol "BUX" and no action is needed by current shareholders. Real-time quotes and market information on BioMark Diagnostics Inc. can be found at Rashid Bux, President and CEO, said: "This is a significant milestone for the Company as we aim to increase our presence among American retail and institutional investors, thereby providing enhanced liquidity. As we move toward the commercial launch of our liquid biopsy test for lung cancer, trading on the OTCQB will make it easier for U.S. investors to discover and trade our stock, while benefiting from transparent pricing and reporting standards. The timing is opportune for BioMark, and we believe the uplisting will boost visibility to a broader universe of investors and provide improved liquidity for our stock as the Company seeks to expand its future operations in the US, starting with potential collaborations at some important comprehensive cancer screening centers." About OTCQB The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international companies. The OTCQB is also the premier marketplace for developing companies, including those in the medical technology sector. To be eligible, companies must be current in their reporting and undergo an annual verification and comply with management certification requirements, providing investors with a trusted market for trading. The OTCQX and OTCQB markets are considered 'Established Public Markets' by the SEC for the purpose of determining the public market price when registering securities for resale with the SEC in equity line financing. OTC Markets Group can facilitate electronic trading with its SEC-registered Alternative Trading System known as OTC Link ATS. About BioMark Diagnostics Inc. BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The Company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology. Further information about BioMark is available under its profile on the SEDAR+ website and the CSE website For further information on BioMark, please Contact:Rashid Ahmed Bux President & CEOBioMark Diagnostics 604-370-0779 Email: info@ Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. This press release contains certain forward-looking statements, including statements regarding the anticipated benefits of the Company's OTCQB listing and DTC eligibility, the expected impact on trading liquidity, and the Company's ability to attract a broader U.S. investor base. Forward-looking statements include, but are not limited to, statements identified by words such as "expects", "anticipates", "believes", "intends", "will", "may", and similar expressions, which are intended to identify forward-looking statements. Although the Company believes that its expectations as reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties, including but not limited to general market conditions, investor interest, regulatory changes, and other risk factors that could cause actual results to differ materially from those anticipated. There is no assurance that the OTCQB listing, or DTC eligibility will result in improved liquidity or broader investor access as anticipated. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements. The CSE has not reviewed, approved, or disapproved of the content of this press release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
